oasis 3 semaglutide First oral made a strong impression in OASIS-1 #obesity with 15% #weightloss now orforglipron leads the impressive pack of new small molecule oral GLP-1RA with robust #Weightloss and good tolerability ADA2023 oasis 3 semaglutide Novo Nordisk

Pancreatitis on Ozempic (semaglutide 0.5-2 mg): Incidence, Severity, and Realistic Expectations Pancreatitis on Ozempic (semaglutide 0.5-2 mg): Incidence, Severity, and Realistic Expectations At a glance Incidence in trials: ~0.3% (semaglutide) vs ~0.2% (comparators) across SUSTAIN 1-10 Typical onset: Weeks to months after initiation or dose escalation Severity distribution: Majority mild-to-moderate (Revised Atlanta Classification Grade A/B)

Common side effects include: Nausea Vomiting Diarrhea Stomach pain Constipation Weight loss Serious but less common side effects include: Severe allergic reactions Increased risk of thyroid tumors (including medullary thyroid carcinoma, MTC) Risk of multiple endocrine neoplasia syndrome type 2 (MEN 2) Pancreatitis Diabetic retinopathy complications Hypoglycemia, especially with other diabetes medications Worsening kidney disease Gallbladder disease and gallstones This is not a full list of side effects

"Yeah I was almost two weeks late then it just randomly showed up

The bioavailability of it is very poor, 0.4 1.0%

When might the oral amycretin become available for patients

Ozempic is an FDA-approved drug made by Novo Nordisk